Massachusetts Eye and Ear (Mass. Eye and Ear, or MEE) is a specialty hospital located in Boston, Massachusetts, United States, which focuses on ophthalmology (eye), otolaryngology (ear/nose/throat), and related medicine and research. Founded in 1824 as the Boston Eye Infirmary (BEI), it has also been known as the Massachusetts Charitable Eye and Ear Infirmary (MCEEI), and Massachusetts Eye and Ear Infirmary (MEEI). It is a teaching partner of Harvard Medical School. Massachusetts Eye and Ear has earned an international reputation for its successful treatment of the most difficult diseases and conditions of the eye, ear, nose, throat, head, and neck, and for its outstanding contributions to medical research and education. In 2018, Massachusetts Eye and Ear has two adult specialties nationally ranked the "U.S. News Best Hospitals Rankings and Ratings 2018-18, with the Department of Ophthalmology ranked number four in the U.S. and the Department of Otolaryngology placing number six in the nation.The primary teaching hospital for Harvard Medical School in ophthalmology and otolaryngology, Massachusetts Eye and Ear trains more than 110 residents and fellows each year in its various sub-specialties, including cornea, neuro-ophthalmology, retina, eye pathology, pediatrics, glaucoma, ocular oncology, immunology, head & neck surgery, oncology, pediatric otolaryngology, facial plastics, otology and oto-neurology. In addition to ophthalmology and otolarynology, the hospital provides patient services and conducts research and clinical training in audiology (diagnostics, hearing aids and cochlear implants), balance (vestibular), facial nerve, thyroid, voice and speech, and vision rehabilitation.
Avian influenza viruses, particularly the H5N1 subtype, represent a major global threat due to their high transmissibility and mortality rates. Rapid, low-cost, and reliable detection is essential for controlling viral spread in both avian and human populations. This work presents a microfluidic electronic tongue composed of interdigitated electrodes functionalized with one-layer, nanostructured films from renewable sources zein, jacalin, concanavalin A, and sericin-modified gold nanoparticles (AuNP-SER) for the detection of anti-H5N1 antibodies. Electrical impedance spectroscopy was employed to monitor the interaction between antibodies and molecular architectures, supported by contact angle and polarization-modulated infrared reflection absorption spectroscopy (PM-IRRAS) analyses to elucidate the detection mechanism. The sensors exhibited high sensitivity and selectivity, with limits of detection ranging from 0.42 to 0.56 ng/mL and no false positives when tested against common avian disease antibodies. Information visualization techniques demonstrated strong discrimination among analytes, with silhouette coefficients up to 0.81 for the electronic tongue. Using the multidimensional calibration space (MCS) approach with decision-tree models, the system achieved 78% accuracy in multiclass classification of 10 antibody concentrations and 98.6% accuracy in distinguishing positive from negative samples. The MCS revealed that the 2154 Hz frequency from the AuNP-SER unit was influential in both scenarios. These results confirm the potential of the electronic tongue proposed as a robust, interpretable, and low-cost diagnostic tool for H5N1-related diseases in veterinary and clinical contexts.
Purpose: To describe the epidemiology, clinical features, and visual outcomes after intraocular foreign body (IOFB) removal. Design: Retrospective multicenter cohort study using data from the American Academy of Ophthalmology IRIS (R) Registry (Intelligent Research in Sight). Subjects: Eyes that underwent IOFB removal between January 2016 and October 2024. Methods: Sociodemographic information, clinical features at presentation, primary surgical procedures, and postoperative complications were summarized. Multivariable linear mixed-effects regression models were employed to investigate predictors of visual outcomes up to 18 months post-IOFB removal. Main Outcome Measure: Epidemiology (including annual incidence rates and associated factors) and clinical characteristics and predictors of visual acuity (VA) up to 18 months after IOFB removal. Results: A total of 4784 eyes (4684 patients, 70.3% male) with a median age of 55 years at presentation (inter-quartile range, 36-70) were identified over the study period. Mean annual incidence was estimated at 2.28 per 100 000 patient-years (95% confidence interval, 2.09-2.49) and was independently associated with male sex, race, and rural residence. The most common complications at presentation were retinal detachment (12.5%), cataract (10.5%), vitreous hemorrhage (7.9%), and endophthalmitis (3.9%). Median VA at presentation was 1.24 logarithm of the minimum angle of resolution (LogMAR) (interquartile range, 0.30-2.30). A significant improvement in VA was seen only from month 2 post-IOFB removal (-0.38 LogMAR; 95% confidence interval, -0.41 to -0.34), with further minor improvements up to month 18 (-0.59 LogMAR; 95% confidence interval, -0.69 to -0.48). After adjusting for relevant covariates, Black or African American race and the presence of endophthalmitis, retinal detachment, or hyphema at baseline were associated with worse visual outcomes. Subgroup analysis of patients who had pre-IOFB VA found that improvement was attenuated for people with pre-IOFB VA worse than 1.0 LogMAR. Conclusions: These findings offer a real-world benchmark for post-IOFB visual trajectories and outcomes and may support clinicians in prognostication and patient counseling. Further research is needed to investigate the underlying drivers of observed racial disparities to inform equitable care. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. Ophthalmology Retina 2026;10:411-419 (c) 2025 by the American Academy of Ophthalmology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
We aim to validate the previously published FIRST-ROP algorithm in a tertiary-level center. This is a retrospective consecutive study that includes premature infants screened for retinopathy of prematurity (ROP) at a tertiary referral center in Thessaloniki, Greece. Infants who did not meet criteria for microprematurity or nanoprematurity (i.e., infants born at ≥ 27 weeks gestational age and weighing ≥ 800 g) were included in the study. Of the 1251 infants screened, 1094 (87.4
Importance:Recurrence rates for locally advanced human papillomavirus (HPV)-independent head and neck squamous cell carcinoma (HNSCC) are high. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assays have shown promise to improve management and surveillance in several tumor types, but their clinical utility in HPV-independent HNSCC remains understudied. Objective:To evaluate the performance of a tumor-informed ctDNA-based MRD assay in patients with newly diagnosed locally advanced HNSCC. Design, Setting, and Participants:Between December 2020 and March 2022, among patients newly diagnosed with locally advanced HNSCC treated with surgery followed by risk-adjusted adjuvant treatment at a large referral center specializing in treatment of HNSCC, ctDNA was assessed before surgery, before the start of adjuvant treatment, within 6 weeks of completion of treatment, and during surveillance. Patients were followed up for at least 12 months after treatment completion. Kaplan-Meier survival analyses were used to compare recurrence-free survival (RFS) and overall survival (OS) between patients who were MRD positive and those who were MRD negative during each time window. Multivariable Cox hazard regressions were used to assess the association between MRD status and outcomes while controlling for established risk factors. Data were analyzed from August 2024 to March 2025. Intervention:Tumor-informed ctDNA-based MRD testing. Main Outcomes and Measures:RFS and OS. Results:Of 40 included patients, 29 (73%) were male, 38 (95%) had HPV-independent disease, and the median (IQR) age at diagnosis was 63 (28-85) years. A total of 142 samples from 40 patients. A total of 20 patients (50%) experienced recurrence. The presurgery ctDNA detection rate was 97% (35 of 36). MRD positivity within 6 weeks of completion of treatment was associated with worse OS (hazard ratio [HR], 7.15; 95% CI, 1.44-35.34) and RFS (HR, 5.39; 95% CI, 1.98-21.07). MRD positivity during surveillance was associated with worse RFS (HR, 8.27; 95% CI, 2.03-33.64). The median (range) time from first MRD detection to clinical detection of recurrence was 5 (0.2-21.6) months. In multivariable analyses, MRD positivity was associated with worse RFS (HR, 13.84; 95% CI, 2.92-65.68) and worse OS (HR, 18.93; 95% CI, 2.27-157.70). Conclusions and Relevance:In this study, tumor-informed ctDNA MRD positivity was associated with worse RFS and OS in patients with HNSCC. MRD testing could serve as a noninvasive, prognostic biomarker in patients with HPV-independent HNSCC.
Thyroid tumors with questionable capsular invasion (CI) or angioinvasion (AI) pose diagnostic and management challenges. The World Health Organization (WHO) recognizes these borderline entities as follicular tumors of uncertain malignant potential (FT-UMP) or well-differentiated tumors of uncertain malignant potential (WDT-UMP). We have conducted a retrospective, single-center study of all thyroid tumors diagnosed as UMP (2005–2025). Of 534 tumors initially labeled “uncertain malignant potential,” application of exclusion criteria yielded 324 tumors from 318 patients with questionable CI and/or AI. Clinicopathological characteristics, molecular testing data, postoperative laboratory values, imaging, and outcomes were analyzed. UMP was diagnosed in 0.5